ATE477269T1 - Tolerogene peptide des basischen myelinproteins - Google Patents
Tolerogene peptide des basischen myelinproteinsInfo
- Publication number
- ATE477269T1 ATE477269T1 AT03701612T AT03701612T ATE477269T1 AT E477269 T1 ATE477269 T1 AT E477269T1 AT 03701612 T AT03701612 T AT 03701612T AT 03701612 T AT03701612 T AT 03701612T AT E477269 T1 ATE477269 T1 AT E477269T1
- Authority
- AT
- Austria
- Prior art keywords
- myelin protein
- basic myelin
- peptide
- tolerogenic peptides
- peptides
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 5
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- 102000006386 Myelin Proteins Human genes 0.000 title 1
- 108010083674 Myelin Proteins Proteins 0.000 title 1
- 230000003614 tolerogenic effect Effects 0.000 title 1
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 abstract 2
- 102000047918 Myelin Basic Human genes 0.000 abstract 2
- 101710107068 Myelin basic protein Proteins 0.000 abstract 2
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 abstract 1
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 abstract 1
- 102000043129 MHC class I family Human genes 0.000 abstract 1
- 108091054437 MHC class I family Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Rehabilitation Therapy (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0202399.2A GB0202399D0 (en) | 2002-02-01 | 2002-02-01 | Peptide |
| PCT/GB2003/000399 WO2003064464A1 (en) | 2002-02-01 | 2003-01-30 | Tolerogenic peptides from myelin basic protein |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE477269T1 true ATE477269T1 (de) | 2010-08-15 |
Family
ID=9930251
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03701612T ATE477269T1 (de) | 2002-02-01 | 2003-01-30 | Tolerogene peptide des basischen myelinproteins |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US7071297B2 (de) |
| EP (1) | EP1474443B1 (de) |
| JP (1) | JP4559082B2 (de) |
| KR (1) | KR20040108650A (de) |
| CN (1) | CN100482685C (de) |
| AT (1) | ATE477269T1 (de) |
| AU (1) | AU2003202701B2 (de) |
| BR (1) | BRPI0307276B8 (de) |
| CA (1) | CA2473469C (de) |
| CO (1) | CO5601035A2 (de) |
| CY (1) | CY1110862T1 (de) |
| DE (1) | DE60333728D1 (de) |
| DK (1) | DK1474443T3 (de) |
| ES (1) | ES2349463T3 (de) |
| GB (1) | GB0202399D0 (de) |
| MX (1) | MXPA04007510A (de) |
| NO (1) | NO332446B1 (de) |
| NZ (1) | NZ534233A (de) |
| PL (1) | PL212129B1 (de) |
| PT (1) | PT1474443E (de) |
| SI (1) | SI1474443T1 (de) |
| WO (1) | WO2003064464A1 (de) |
| ZA (1) | ZA200405546B (de) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102764425B (zh) | 2000-08-21 | 2015-11-25 | 阿皮托普技术(布里斯托尔)有限公司 | 肽选择方法 |
| EP2134176A4 (de) * | 2007-03-30 | 2012-08-29 | Brigham & Womens Hospital | Verbindungen und verfahren zur verbesserung von mhc-klasse-ii-therapien |
| ATE518546T1 (de) * | 2007-10-31 | 2011-08-15 | Apitope Technology Bristol Ltd | Zusammensetzungen enthaltend myelin-basisches protein peptiden und medizinische verwendungen |
| EP2488196B1 (de) | 2009-10-12 | 2015-12-16 | LIFEBio Laboratories LLC | Zusammensetzung zur behandlung von multipler sklerose |
| EP2603520A4 (de) | 2010-08-10 | 2014-02-19 | Ecole Polytech | Erythrozytenbindende therapeutika |
| US9517257B2 (en) | 2010-08-10 | 2016-12-13 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
| US9850296B2 (en) | 2010-08-10 | 2017-12-26 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
| GB201314052D0 (en) * | 2013-08-06 | 2013-09-18 | Apitope Int Nv | Peptides |
| US10953101B2 (en) | 2014-02-21 | 2021-03-23 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
| SG11201606761RA (en) | 2014-02-21 | 2016-09-29 | Ecole Polytecnique Federale De Lausanne Epfl Epfl Tto | Glycotargeting therapeutics |
| US10046056B2 (en) | 2014-02-21 | 2018-08-14 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
| US10946079B2 (en) | 2014-02-21 | 2021-03-16 | Ecole Polytechnique Federale De Lausanne | Glycotargeting therapeutics |
| ES2996234T3 (en) | 2014-12-24 | 2025-02-12 | Worg Pharmaceuticals Zhejiang Co Ltd | Composition |
| EP3344575B1 (de) | 2015-09-04 | 2020-04-15 | SQZ Biotechnologies Company | Intrazelluläres einbringen von biomolekülen in zellen mit einer zellwand |
| EP4212547A1 (de) | 2015-12-03 | 2023-07-19 | Juno Therapeutics, Inc. | Modifizierte chimäre rezeptoren und zugehörige zusammensetzungen und verfahren |
| CA3023092A1 (en) | 2016-05-03 | 2017-11-09 | Sqz Biotechnologies Company | Intracellular delivery of biomolecules to induce tolerance |
| US20200046802A1 (en) * | 2017-01-04 | 2020-02-13 | Apitope International Nv | Therapeutic method using tolerogenic peptides |
| WO2018232176A1 (en) | 2017-06-16 | 2018-12-20 | The University Of Chicago | Compositions and methods for inducing immune tolerance |
| CN110317254A (zh) * | 2018-03-28 | 2019-10-11 | 深圳市安群生物工程有限公司 | 人mbp抗原表位肽、抗原、抗体、应用及化学发光试剂盒 |
| EP3790577A4 (de) | 2018-05-09 | 2022-04-27 | The University of Chicago | Zusammensetzungen und verfahren im zusammenhang mit immuntoleranz |
| EP3586866A1 (de) | 2018-06-28 | 2020-01-01 | Universität Zürich | Immunodominante proteine und fragmente bei multipler sklerose |
| EP4058006A4 (de) | 2019-11-11 | 2023-06-28 | The Regents Of The University Of California | Polymere nanopartikel, die auf sinusoidale endothelzellen der leber abzielen, um antigenspezifische immuntoleranz zu induzieren |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6077509A (en) * | 1990-03-30 | 2000-06-20 | Autoimmune, Inc. | Peptide fragments of myelin basic protein |
| HUT76099A (en) * | 1994-05-10 | 1997-06-30 | Immulogic Pharma Corp | Compositions and treatment for multiple sclerosis |
| IL115766A0 (en) * | 1994-10-25 | 1996-01-19 | Immulogic Pharma Corp | Composition and treatment for multiple sclerosis |
| CN102764425B (zh) * | 2000-08-21 | 2015-11-25 | 阿皮托普技术(布里斯托尔)有限公司 | 肽选择方法 |
-
2002
- 2002-02-01 GB GBGB0202399.2A patent/GB0202399D0/en not_active Ceased
-
2003
- 2003-01-30 BR BRPI0307276A patent/BRPI0307276B8/pt not_active IP Right Cessation
- 2003-01-30 PL PL371549A patent/PL212129B1/pl unknown
- 2003-01-30 SI SI200331890T patent/SI1474443T1/sl unknown
- 2003-01-30 KR KR10-2004-7011906A patent/KR20040108650A/ko not_active Withdrawn
- 2003-01-30 EP EP03701612A patent/EP1474443B1/de not_active Expired - Lifetime
- 2003-01-30 ES ES03701612T patent/ES2349463T3/es not_active Expired - Lifetime
- 2003-01-30 DK DK03701612.8T patent/DK1474443T3/da active
- 2003-01-30 NZ NZ534233A patent/NZ534233A/en not_active IP Right Cessation
- 2003-01-30 DE DE60333728T patent/DE60333728D1/de not_active Expired - Lifetime
- 2003-01-30 MX MXPA04007510A patent/MXPA04007510A/es active IP Right Grant
- 2003-01-30 JP JP2003564084A patent/JP4559082B2/ja not_active Expired - Fee Related
- 2003-01-30 WO PCT/GB2003/000399 patent/WO2003064464A1/en not_active Ceased
- 2003-01-30 AT AT03701612T patent/ATE477269T1/de active
- 2003-01-30 CN CNB038030772A patent/CN100482685C/zh not_active Expired - Fee Related
- 2003-01-30 CA CA2473469A patent/CA2473469C/en not_active Expired - Lifetime
- 2003-01-30 PT PT03701612T patent/PT1474443E/pt unknown
- 2003-01-30 AU AU2003202701A patent/AU2003202701B2/en not_active Ceased
-
2004
- 2004-07-13 ZA ZA2004/05546A patent/ZA200405546B/en unknown
- 2004-07-27 US US10/900,032 patent/US7071297B2/en not_active Expired - Lifetime
- 2004-07-28 NO NO20043210A patent/NO332446B1/no not_active IP Right Cessation
- 2004-08-26 CO CO04083647A patent/CO5601035A2/es not_active Application Discontinuation
-
2010
- 2010-10-27 CY CY20101100972T patent/CY1110862T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20040108650A (ko) | 2004-12-24 |
| MXPA04007510A (es) | 2005-07-13 |
| CN1625564A (zh) | 2005-06-08 |
| ZA200405546B (en) | 2005-09-28 |
| PL371549A1 (en) | 2005-06-27 |
| NO20043210L (no) | 2004-11-01 |
| BRPI0307276B1 (pt) | 2019-08-13 |
| JP4559082B2 (ja) | 2010-10-06 |
| AU2003202701B2 (en) | 2009-01-08 |
| PL212129B1 (pl) | 2012-08-31 |
| NZ534233A (en) | 2006-04-28 |
| SI1474443T1 (sl) | 2010-12-31 |
| CY1110862T1 (el) | 2015-06-10 |
| EP1474443B1 (de) | 2010-08-11 |
| EP1474443A1 (de) | 2004-11-10 |
| HK1066551A1 (en) | 2005-03-24 |
| BRPI0307276B8 (pt) | 2021-05-25 |
| US20050058643A1 (en) | 2005-03-17 |
| CO5601035A2 (es) | 2006-01-31 |
| CA2473469A1 (en) | 2003-08-07 |
| DE60333728D1 (de) | 2010-09-23 |
| US7071297B2 (en) | 2006-07-04 |
| CA2473469C (en) | 2012-04-24 |
| ES2349463T3 (es) | 2011-01-03 |
| GB0202399D0 (en) | 2002-03-20 |
| CN100482685C (zh) | 2009-04-29 |
| WO2003064464A1 (en) | 2003-08-07 |
| BR0307276A (pt) | 2004-12-14 |
| NO332446B1 (no) | 2012-09-17 |
| JP2005531497A (ja) | 2005-10-20 |
| PT1474443E (pt) | 2010-10-26 |
| DK1474443T3 (da) | 2010-10-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1110862T1 (el) | Πεπτιδια που προκαλουν ανοσολογικη ανοχη απο βασικη πρωτεϊνη της μυελινης | |
| PH12013500208A1 (en) | Tolerogenic peptides from myelin basic priotein | |
| BR9814276A (pt) | Antìgenos de superfìcie | |
| BRPI0211200B8 (pt) | peptídeos efetivos no tratamento de tumores e outras condições que requerem a remoção ou destruição de células | |
| EA200401471A1 (ru) | Применение ингибиторов сетр и возможных ингибиторов hmg coa и/или антигипертензивных агентов | |
| ATE397016T1 (de) | Von rasgap-abgeleitetes peptid zur gezielten tötung von krebszellen | |
| BRPI0414157A (pt) | polipeptìdeo isolado, ácido nucleico isolado, método para inibir a infecção por vìrus da sìndrome da mancha branca de um crustáceo, e, alimento para um crustáceo | |
| ATE326981T1 (de) | Isolierte peptide die aminosäuresequenzen von ny- eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen | |
| ATE401400T1 (de) | Antiangiogene peptide zur behandlung oder vorbeugung von endometriose | |
| DE3584775D1 (de) | Zusammensetzung zur behandlung von an haemophilia-a-inhibitor leidenden kranken. | |
| FR2828405B1 (fr) | Vaccin anti-coronavirus | |
| NO942323L (no) | Soyaprotein eller hydrolysater i farmasöytiske preparater for beskyttelse av bioaktive peptider mot enzymatisk inaktivering | |
| WO2006029125A3 (en) | Methods and compositions for treating hypercholesterolemia | |
| MX9700199A (es) | Composiciones de cadena invariante utiles para tratar enfermedades autoinmunes. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1474443 Country of ref document: EP |